MedTrace Logo

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

NCT06624878 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 568

Last updated 2026-02-27

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer. The main questions it aims to answer are:

* Whether a single low dose of esketamine administered would reduce the postoperative depressive symptoms three days after cytoreductive surgery in ovarian cancer?
* Whether a single low dose of esketamine administered would relief the postoperative sleep disturbance, postoperative recovery? Researchers will compare the esketamine to a placebo (normal saline) to see if the esketamine works to reduce the postoperative depressive symptoms.

Participants will:

* Receive either 0.2 mg/kg esketamine or placebo infused intravenously after induction of general anesthesia.
* The preoperative Patient Health Questionnaire 9 (PHQ-9) scale was used to verify the symptoms suggestive of depression.

Conditions

Interventions

DRUG

placebo

a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.

DRUG

esketamine

0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2026-01-14
Completion
2026-02-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06624878 on ClinicalTrials.gov